Update in the pharmaceutical therapy of the irritable bowel syndrome

International Journal of Clinical Practice

Volumn 58, Issue 4, 2004, Pages 374-381

  Thielecke, Frank ^a   Maxion Bergemann, S ^a   Abel, F ^b   Gonschior, A K ^b  

^a Inst for Med Outcome Research GmbH   (Germany)

^b Atlanta Pharma   (Germany)

Author keywords

Brain gut axis; Irritable bowel syndrome; Serotonin receptor modulators

Indexed keywords

ALOSETRON; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETROPIUM; CISAPRIDE; DICYCLOVERINE; FEDOTOZINE; GRANISETRON; HYOSCYAMINE; IMIPRAMINE; KAPPA OPIATE RECEPTOR AGONIST; LOPERAMIDE; MEBEVERINE; MESALAZINE; ONDANSETRON; OPIATE AGONIST; OTILONIUM BROMIDE; PINAVERIUM; PLACEBO; PROKINETIC AGENT; PRUCALOPRIDE; PSYCHOTROPIC AGENT; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR AFFECTING AGENT; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE; UNINDEXED DRUG;

CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CULTURAL FACTOR; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTITIONER; HEART ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IRRITABLE COLON; MONOTHERAPY; NERVOUS SYSTEM; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QT PROLONGATION; REVIEW; SIDE EFFECT; SOCIAL ASPECT; TORSADE DES POINTES; UNITED STATES;

GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; IRRITABLE BOWEL SYNDROME; MOOD DISORDERS; PAIN; PSYCHOTROPIC DRUGS; SENSATION; VISCERA;

EID: 2642535880     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00136.x     Document Type: Review

References (63)

1. Saito YA, Locke GR, Talley NJ et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Dig Dis Sci 2000; 95 (10): 2816-24.
2. Balboa A, Mearin F. Epidemiological characteristics and socioeconomic importance of irritable bowel syndrome. Rev Esp Enferm Dig 2000; 92 (12): 806-19.
3. Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992; 304 (6819): 87-90.
4. Longstreth GF. Irritable bowel syndrome: a multibillion-dollar problem. Gastroenterology 1995; 109 (6): 2029-31.
5. Drossman DA, Li Z, Andruzzi E et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38 (9): 1569-80.
6. Creed F, Ratcliffe J, Fernandez L et al. Health-related quality of life and health care costs in sever, refractory irritable bowel syndrome. Ann Intern Med 2001; 134 (9Pt2): 860-80.
7. Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999; 45 (Suppl. 2): II1-II5.
8. Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Prim Care 1997; 11 (6): 1019-30.
9. Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999; 60 (1): 77-81.
10. Silverman DH, Munakata JA, Ennes H et al. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997; 112 (1): 64-72.
11. Mertz H, Morgan V, Tanner G et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000; 118 (5): 842-8.
12. Wood JD, Alpers DH, Andrews PL. Fundamentals of neurogastroenterology. Gut 1999; 45 (Suppl. 2): II6-II16.
13. Alaradi O, Barkin JS. Irritable bowel syndrome: update on pathogenesis and management. Med Principles Pract 2002; 11 (1): 2-17.
14. Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut 2002; 51 (Suppl. 1): i67-i71.
15. Schikowski A. Dose-dependent modulation of rectal afferent sensitivity by a A-5-HT4 receptor antagonist. Gastroenterology 1999; 118 (4): A 643. [Abstract].
16. Villanueva A, Dominguez-Munoz JE, Mearin F. Update in the therapeutic management of irritable bowel syndrome. Dig Dis 2001; 19 (3): 244-50.
17. Farthing MJ. Irritable bowel syndrome: new pharmaceutical approaches to treatment. Baillieres Best Pract Res Clin Gastroenterol 1999; 13 (3): 461-71.
18. Schwartz D, Stollman N. University of Miami Division of Clinical Pharmacology therapeutic rounds: irritable bowel syndrome-pathophysiology, diagnosis, and treatment. Am J Ther 2000; 7 (4): 265-72.
19. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002; 360 (9332): 555-64.
20. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358 (9298): 2061-8.
21. Whitehead WE, Bosmajian L, Zonderman AB et al. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Gastroenterology 1988; 95 (3): 709-14.
22. Whitehead WE. Psychosocial aspects of functional gastrointestinal disorders. Gastroenterol Clin North Am 1996; 25 (1): 21-34.
23. Fukudo S, Nomura T, Muranaka M et al. Brain-gut response to stress and cholinergic stimulation in irritable bowel syndrome. A preliminary study. J Clin Gastroenterol 1993; 17 (2): 133-41.
24. Talley NJ. Irritable bowel syndrome: disease definition and symptom description. Eur J Surg Suppl 1998; 583: 24-8.
25. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112 (6): 2120-37.
26. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122 (4): 1140-56.
27. Sperber AD, Atzmon Y, Neumann L et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 1999; 94 (12): 3541-6.
28. Endicott NA. Chronic fatigue syndrome in psychiatric patients: lifetime and premorbid personal history of physical health. Psychosom Med 1998; 60 (6): 744-51.
29. Zondervan KT, Yudkin PL, Vessey MP et al. Patterns of diagnosis and referral in women consulting for chronic pelvic pain in UK primary care. Br J Obstet Gynaecol 1999; 106 (11): 1156-61.
30. Callahan MJ. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol 2002; 35 (1 Suppl.): S58-S67.
31. Farup PG, Hovdenak N, Wetterhus S et al. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998; 33 (2): 128-31.
32. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133 (2): 136-47.
33. Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161 (14): 1733-40.
34. Watson ME, Lacey L, Kong S et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96 (2): 455-9.
35. Mayer EA, Chang L, Lembo T. Brain-gut interactions: implications for newer therapy. Eur J Surg Suppl 1998; 582: 50-5.
36. Camilleri M. Serotonergic modulation of visceral sensation: lower gut. Gut 2002; 51 (Suppl. 1): i81-i86.
37. Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Prim Care 1999; 13 (9): 1149-59.
38. Moynihan R. Alosetron: a case study in regulatory capture, or a victory for patients' rights? BMJ 2002; 325 (7364): 592-5.
39. Scott LJ, Perry CM. Tegaserod. Drugs 1999; 58 (3): 491-6.
40. Jones BW, Moore DJ, Robinson SM et al. A systematic review of tegaserod for the treatment of irritable bowel syndrome. J Clin Pharm Ther 2002; 27 (5): 343-52.
41. Tougas G, Snape WJ, Otten MH et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Prim Care 2002; 16 (10): 1701-8.
42. Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Prim Care 2002; 16 (11): 1877-88.
43. Crawford LM Jr. From the food and drug administration. JAMA 2002; 288 (10): 1225.
44. Lacy Brian E, Yu S. Tegaserod, a new 5-HT4 agonist. J Clin Gastroenterol 2002; 34: 27-33.
45. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95 (10): 2698-709.
46. Degen L, Matzinger D, Merz M et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Prim Care 2001; 15 (11): 1745-51.
47. Prather CM, Camilleri M, Zinsmeister AR et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118 (3): 463-8.
48. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115 (2): 370-80.
49. Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52 (5): 671-6.
50. Fidelholtz J, Smith W, Rawls J et al. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Dig Dis Sci 2002; 97 (5): 1176-81.
51. Muller-Lissner SA, Fumagalli I, Bardhan KD et al. Tegaserod, a 5-HT (4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Prim Care 2001; 15 (10): 1655-66.
52. Camilleri M. Review article: tegaserod. Prim Care 2001; 15 (3): 277-89.
53. Gysling E. Tegaserod. Pharma-Kritik 2001; 23 (18): 71-2.
54. Grueger J. Cost-effectiveness of Zelmac in the treatment of IBS in Switzerland. Novartis Pharma AG Basel: Switzerland, 2002. [Ref Type: Generic].
55. Trallori G, Messori A. Drug treatments for maintaining remission in Crohn's disease. A lifetime cost-utility analysis. Pharmacoeconomics 1997; 11 (5): 444-53.
56. Moss HE, Sanger GJ. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol 1990; 100 (3): 497-501.
57. Steadman CJ, Talley NJ, Phillips SF et al. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 1992; 67 (8): 732-8.
58. Lydiard RB. Irritable bowel syndrome, anxiety, and depression: What are the links? J Clin Psychiatry 2001; 62: 38.
59. Jackson JL, O'Malley PG, Tomkins G et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108 (1): 65-72.
60. Fioramonti J, Bueno L. Centrally acting agents and visceral sensitivity. Gut 2002; 51 (Suppl. 1): i91-i95.
61. Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry 1999; 60 (5): 326-35.
62. Manning AP, Thompson WG, Heaton KW et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2 (6138): 653-4.
63. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl. 2): II43-II47.